Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Bifidobacterium animalis subsp. lactis BB-12 and Improved Intestinal Barrier Function

Research synthesisVery low evidenceModerate effect4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial effects of Bifidobacterium animalis subsp. lactis BB-12 on intestinal barrier function, with effect sizes ranging from small to moderate. Two studies showed moderate effects, one showed a small effect, and one did not specify an effect size. The evidence is primarily from in vitro and animal models, with no human trials and no statistically significant findings reported. No consistent dose or study duration was identified.

Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. All findings were beneficial, but none reached statistical significance, and most studies were in vitro or animal models (colitis disease, Caco-2 cells, DNBS-induced colitis in mice), limiting generalizability to humans. The available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).

Generated Jun 11, 2026
4 of 4 papers
Back to top